X
Search
X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

- test

FDA Approves Jevtana for Prostate Cancer Subset

Jevtana (cabazitaxel) was granted approval by the Food and Drug Administration (FDA) for the treatment of men with metastatic castration-resistant... Read More

Expert Weighs In: Active Surveillance in Prostate Cancer

When it comes to active surveillance and prostate-specific antigen (PSA) screening for localized prostate cancer, the paradigm has been shifting... Read More

Learning to Speak Up With Cancer

What stands in the way of patient-physician communications and how can we get around these barriers? Read more. 

Recent Patterns Indicate PSA Testing Halt in Decline

Previously reported declines in prostate-specific antigen testing have not continued in recent years, and that approximately one-third of men age... Read More

Discussing The Latest Advances in Prostate Cancer Treatment

In an interview with CURE at the Interdisciplinary Prostate Cancer Congress, Celesita Higano, M.D., discussed the early use of chemotherapy,... Read More

Personalizing Treatment With ctDNA in Prostate Cancer

Since it is found in the majority of patients with mCRPC, circulating tumor DNA may be able to lead the way... Read More

New Marker Identifies Men With Prostate Cancer at Risk for Death

Men who are at high-risk for death from prostate cancer and require more aggressive treatment may be able to be... Read More

New Marker Identifies Men With Prostate Cancer at Risk for Death

Men who are at high-risk for death from prostate cancer and require more aggressive treatment may be able to be... Read More

Chemotherapy Remains a Mainstay in Advanced Prostate Cancer

Chemotherapy is still a mainstay in the treatment of advanced prostate cancer, and recent studies showed great benefits with docetaxel... Read More

Triplet Does Not Improve Survival in Prostate Cancer

Adding Xtandi to Zytiga and prednisone did not improve progression-free survival for patients with metastatic castration-resistant prostate cancer, according to a recent study.... Read More

1 2